HemoBioTech, Inc. Findings Show Significant Promise For Combating Two Major Complications Involved In Treating Patients With Coronary Artery Disease

DALLAS--(BUSINESS WIRE)--HemoBioTech, Inc. (OTCBB: HMBT), a biopharmaceutical company focused on developing the first commercial substitute for human blood, has gathered results from a pre-clinical study of its HemoTech blood substitute product in patients undergoing percutaneous coronary intervention (PCI) through angioplasty and stent implantation, the most common PCI procedures. HemoBioTech scientists are scheduled to present the study’s findings at two international industry conferences later this month.